鼻咽癌是一種在我國(guó)南方地區(qū)高發(fā)的惡性腫瘤，中晚期患者生存率低，患者放射治療后易復(fù)發(fā)。鼻咽癌的治療仍然是個(gè)很大的挑戰(zhàn)。藥物治療對(duì)中晚期鼻咽癌的治療至關(guān)重要。根據(jù)藥物的抗腫瘤作用機(jī)制，對(duì)誘導(dǎo)細(xì)胞凋亡、放射增敏、逆轉(zhuǎn)多藥耐藥性以及分子靶向治療的抗鼻咽癌藥物進(jìn)行綜述，以期對(duì)藥物開發(fā)和應(yīng)用提供一定的理論依據(jù)。

Nasopharyngeal carcinoma (NPC) is a highly prevalent malignant tumor in southern China. It is found a low survival rate and more likely to recur after radiotherapy for patients with advanced nasopharyngeal carcinoma. Treatment of NPC remains one of the big challenges. Medical therapy has been crucial to the treatments of NPC. The drugs of induced apoptosis, radiosensitization, multidrug resistance and molecular target according to the mechanism of action are reviewed in this paper, in order to provide theoretical basis for drug development and use.

福建省自然科學(xué)基金資助項(xiàng)目（2017J01141、2017J01142）；福建省科技計(jì)劃社會(huì)發(fā)展引導(dǎo)性（重點(diǎn)）（2014Y0051）；福建省省屬公益類科研院所基本科研專項(xiàng)（2015R1031-4、2015R1031-1）；福建省衛(wèi)生與計(jì)劃生育委員會(huì)中醫(yī)藥科研項(xiàng)目（2017FJZYZY101）